Purpose: In brain tumor dynamic susceptibility contrast (DSC)-MRI studies, multiecho acquisition methods are used to quantify the dynamic changes in T 1 and T 2 * that occur when contrast agent (CA) extravasates. Such methods also enable the estimation of the effective tissue CA transverse relaxivity. The goal of this study was to evaluate the sensitivity of the transverse relaxivity at tracer equilibrium (TRATE) to tumor cytoarchitecture. Methods: Computational and in vitro studies were used to evaluate the biophysical basis of TRATE. In 9L, C6, and human brain tumors, TRATE, the apparent diffusion coefficient (ADC), the CA transfer constant (K trans ), the extravascular extracellular volume fraction (v e ), and histological data were compared. Results: Simulations and in vitro results indicate that TRATE is highly sensitive to variations in cellular properties such as cell size and density. The histologic cell density and TRATE values were significantly higher in 9L tumors as compared to C6 tumors. In animal and human tumors, a voxel-wise comparison of TRATE with ADC, v e , and K trans maps showed low spatial correlation. Conclusion: The assessment of TRATE is clinically feasible and its sensitivity to tissue cytoarchitectural features not present in other imaging methods indicate that it could potentially serve as a unique structural signature or "trait" of cancer. Magn Reson Med 74:772-784, 2015. V C 2014 Wiley Periodicals, Inc.
INTRODUCTION
The assessment of perfusion parameters using dynamic susceptibility contrast (DSC)-MRI has proven useful for assessing tumor grade (1-7) and treatment response (3, (8) (9) (10) (11) (12) . In normal brain regions, with an intact bloodbrain barrier (BBB), the biophysical basis of the acquired DSC-MRI signal is well characterized, primarily reflecting the underlying contrast agent (CA) kinetics and vascular geometry (13) . When the BBB is disrupted, small molecular weight contrast agents (CA), such as gadolinium-diethylenetriaminepentaacetic acid (Gd-DTPA) may extravasate, leading to dynamic changes in the tissue T 1 , T 2 , and T 2 * relaxation times. In such cases, DSC-MRI signals are more complex and depend on hemodynamics, vascular geometry and permeability, the extravascular microstructure and the applied pulse sequence (14) (15) (16) . When DSC-MRI signals are acquired and processed without consideration of CA extravasation, the derived hemodynamic parameters are well known to be unreliable (4, 5, 17) . Several techniques have been proposed and used to correct for T 1 and T 2 * leakage effects (14, (17) (18) (19) (20) (21) (22) .
In addition to improving the reliability of DSC-MRI data acquired in the presence of CA leakage, there is an increased interest in leveraging the temporal characteristics of such signals to estimate additional biological information. Pharmacokinetic modeling of DSC-MRI signals in brain tumors has been used to extract CA extravasation rate constants (e.g., K trans ) and the extravascular extracellular volume fraction (v e ) (18, (22) (23) (24) (25) (26) . The appearance of leakage effects on DSC-MRI signals, whether they are predominantly T 1 or T 2 *-based, has been characterized by the percent signal recovery (PSR), a parameter potentially capable of differentiating between gliomas, metastasis and lymphomas (27) . Recent studies have shown that CA leakage-induced T 2 * effects are dependent upon the extravascular geometry (14) (15) (16) 28, 29) and by quantifying these effects, new imaging biomarkers may be derived (16) . Once validated, such parameters could improve the characterization of brain tumors.
Currently, multiecho DSC-MRI, along with a precontrast T 1 map, is used to characterize T 1 and T 2 * leakage effects, as this enables their simultaneous separation and quantification (15, 16, 22, 24) . The dynamic T 1 change enables estimation of the tissue CA concentration. Combining the CA concentration with the dynamic T 2 * changes enables the assessment of the tissue CA transverse (T 2 *) relaxivity. Recently, Sourbron et al used this approach in colorectal cancer xenografts to evaluate the vascular and extravascular CA relaxivity, and found that it provided supplementary information on tumor microstructure that is distinct from traditional compartmental volume fraction measurements (16) .
In this study, we aimed to evaluate whether multiecho DSC-MRI derived measures of the transverse relaxivity at tracer equilibrium (TRATE) may be used to evaluate brain tumor cytoarchitecture. To validate the sensitivity of TRATE to tumor cellular features we use threedimensional (3D) biophysical simulations and compare its characteristics in vitro and in two animal brain tumor models that are known to have histologically different cellular properties. We also present initial results of TRATE data in a cohort of glioma patients. The TRATE maps are spatially compared with parameters traditionally derived from DSC-MRI, dynamic contrast enhanced (DCE)-MRI and diffusion weighted imaging (DWI) to preliminarily assess its potential to provide unique sensitivity to microstructural features not assessed with these techniques.
METHODS

Theory
When CA extravasation effects are present, the tissue transverse relaxation rate depends on both dipole-dipole microscopic interactions between the CA and water protons and mesoscopic effects due to magnetic field perturbation induced by CA compartmentalization within vascular walls and around cells. Models have been previously proposed (14) (15) (16) 18) , that incorporate both microscopic and mesoscopic contributions to the measured transverse relaxation rate change (DR 2 *):
Here v e , v i , and v p denote volume fractions of the extravascular extracellular space (EES), extravascular intracellular space (EIS), and vascular space, respectively. C e and C p represent the CA concentration of the EES and the vascular space, r 2p * and r 2e * are the effective T 2 * relaxivities of CA compartmentalized within the vascular space and EES, and r 2 is the CA T 2 relaxivity.
This model expresses the tissue CA concentration (C t ) as the sum of individual compartment CA concentrations weighted by the corresponding volume fractions (C t ¼ v e C e þ v p C p ), and assumes that the CA does not penetrate into cells and a fast water exchange process. At time points well past the first pass of CA, when C e and C p are approximately equivalent, Eq. [1] can be written as:
The first bracketed term in Eq. [2] can be considered the effective tissue transverse relaxivity at CA equilibrium (r Ã 2t;eq ) and will be termed the transverse relaxivity at tracer equilibrium (TRATE) hereafter. With this definition, Eq. [2] simplifies to:
With multiecho DSC-MRI data and a precontrast T 1 map the tissue CA concentration and the DR 2 * can be computed using the extracted T 1 and T 2 * changes, respectively, thereby enabling the computation of TRATE.
Simulations
To investigate the dependence of TRATE on tissue vascular and cellular features, simulated 3D tissue structures were created using randomly packed ellipsoids around fractal tree based vascular networks (29) . Vascular networks that mimic the architecture found in normal and tumor tissue were computed using a fractal tree approach (30, 31) . To achieve cell densities and cellular orientation heterogeneity that approximate those found in vivo, we used randomly packed ellipsoids to model the extravascular space (32) . Magnetic field perturbations induced by susceptibility variations between the simulated tissue compartments and the associated gradient echo transverse relaxation rates were computed using the finite perturber finite difference method (FPFDM) (29) . In addition to a binary 3D matrix that defines the tissue structure, the FPFDM requires, as input, the static magnetic field strength, the susceptibility difference between simulated tissue compartments, the water diffusion coefficient, and pulse sequence parameters.
For CA concentration levels corresponding to tracer equilibrium, the slope of the computed DR 2 * versus C t was used to estimate TRATE. To investigate the relative contribution of the vascular and extravascular features to TRATE measurements, the signal relaxation was computed using tissue models with fixed cellular features and variable vascular volume fractions. Furthermore, to evaluate the dependence of DR 2 * and TRATE on cellular features, such as cell volume fraction and cell size, the vascular volume fraction was kept fixed while these features were systematically varied.
Unless mentioned otherwise, all simulation studies were carried out using the following input parameters. (34) . While the susceptibility-induced relaxation was computed using the FPFDM, the relatively small effects of microscopic transverse relaxation were calculated and included using the product of C t and the Gd-DTPA T 2 relaxivity (r 2 ¼ 4.5 mM À1 s À1 ) (35) . All simulations were performed in Matlab (Mathworks, Natick, MA).
Animal Studies
Measures of TRATE were compared in two rodent brain tumor models, the C6 glioblastoma and 9L gliosarcoma. Seven male Wistar rats and nine male Fischer rats (Harlan, Indianapolis, IN) were inoculated with 1 Â 10 5 C6 and 1 Â 10 5 9L cells (American Type Culture Collection, Manassas, VA), respectively. Before all surgical and imaging procedures, animals were immobilized in a stereotactic head holder. Anesthesia was induced by means of a 5%/95% isoflurane/oxygen mixture and maintained by means of a 2%/95% isoflurane/oxygen mixture.
All experiments were carried out 14-16 days after tumor inoculation and adhered to our institution's animal care and use committee policies. Scans were conducted at 4. , and matrix ¼ 64 2 . After the acquisition of 60 baseline images, a bolus of Gd-DTPA (0.2 mmol kg À1 per body weight) was intravenously delivered using a power injector at an infusion rate of 2.4 mL/min. As described above, the multiecho DSC-MRI sequence was used to quantify T 1 and T 2 * time series. The precontrast T 1 maps were combined with the T 1 -weighted time series to derive DR 1 (36) . The last 2 min of the DR 1 and DR 2 * time series data were then used to compute TRATE using:
where r 1 is the Gd-DTPA T 1 relaxivity (3.9 mM À1 s À1 ) (35) .
The reference region pharmacokinetic model was applied to the DR 1 time series to compute the DCE-MRI parameters, v e and K trans (24, 37) . Furthermore, DWI was performed to estimate ADC maps using a fast spin echo sequence with diffusion gradients applied along three directions. All diffusion data were obtained using For region of interest (ROI) analysis the tumor ROIs were manually defined on the dynamic contrast enhanced images. All voxels exhibiting contrast enhancement on the last image of the dynamic time series were included in the ROI. Same-sized normal tissue ROIs were selected in contralateral brain in the same slices as that used for the tumor ROIs.
To evaluate tumor cellularity, all animals were killed after the MRI exams, the tumor tissue dissected and fixed in 10% formalin, cut into 5-mm sections and stained with hematoxylin and eosin (H&E). The H&E slides were digitally scanned and analyzed to quantify cell nuclei count using an Ariol SL-50 automated scanning microscope. A manual threshold approach is used to discern between the intra-and extracellular spaces to estimate cell volume fraction. The cell nuclei count along with an assumed circular cell shape was used to obtain estimates of the mean cell size for each tumor cell line.
In addition to the animals studies described above in vitro cell studies were also used to investigate the biophysical basis of TRATE as described in Supporting Figure S2 (which is available online).
Clinical Studies
Five patients (4 male 1 female), age (51-66 years old) with a recurrent high-grade glioma was scanned at 3T (Philips Healthcare, Cleveland, OH) using a 32-channel head coil. Multiple FA data was acquired (TR ¼ 7.6 ms,
to produce a T 10 map. Next, a multiecho single-shot echo planar imaging acquisition (TR ¼ 1.5 s, TE1/TE2 ¼ 7/31 ms, FOV ¼ 240 Â 240 mm 2 , ST¼ 5 mm, matrix ¼ 96 2 ) was performed before, during, and after administration of 0.1 mmol/kg Gd-DTPA at an infusion rate of 4 mL/s (followed by a saline flush). The scan duration was 7.5 min and followed all guidelines set by the Vanderbilt University Institutional Review Board. Measures of DR 2 * and DR 1 were calculated from the multiecho data for the entire time-course (36) . DSC-MRI perfusion maps were calculated from the DR 2 * measurements and an automated measure of the arterial input function, using circular SVD-based deconvolution (38) . Maps of K trans , v e , and ADC (DW SE-ssEPI, TR ¼ 6 s, TE¼ 44 ms, number of excitations ¼ 2, b ¼ 100 and 1000 s/mm 2 ) were also computed. Voxel wise estimates of C t and TRATE were calculated using Eq. [4] .
Statistical Analysis
Single variable and multivariable associations between cell density and TRATE in animals were estimated using standard regression analysis. Statistical relationships between TRATE and K trans , ADC, and v e were performed using both ROI and voxel-wise analysis. For ROI analysis, standard linear regression relationships between mean parameters for each animal or patient were used. Voxel-wise prediction of TRATE by cell line, and K trans , ADC, and v e were conducted using analysis of covariance in a generalized linear model assuming a normal distribution, the identity link with an exchangeable covariance working model. Generalized estimating equations were used to account for intravoxel correlation within animals or humans. Standard goodness-of-fit and residual analyses were conducted and found unremarkable. Figure 1 shows example FPFDM simulation results, demonstrating the main input and output parameters. Figure  1A shows a 3D volume rendering of a sample tissue structure, which contains a 60% volume fraction of ellipsoids with an average radii of 15 mm (note that only 1 =4 of the total number of cells are incorporated to aid in structure visualization) and a 6% vascular volume fraction with vessel sizes ranging from 5 mm to 45 mm. For illustrative purposes, the two compartment pharmacokinetic model described by Brix et al was used to create the C e and C p time curves (with clinically relevant input parameters) shown in Figure 1B (39) . Figure 1C shows a representative 2D slice through the tissue structure along with magnetic field perturbations computed at three time points indicated in Figure 1B . For time points near the peak of C p , where C e is very small, the field perturbation is dominated by the vascular structure, as indicated by the strong field perturbations surrounding the vessels. As C e increases, the field perturbation around cells starts to emerge and dominates the vascular field perturbation at time points near CA equilibrium, as illustrated by the elevated field perturbations surrounding ellipsoids. The resulting DR 2 * time curve is shown in Figure 1D .
RESULTS
For CA concentration levels similar to tracer equilibrium and a range of relevant cellular and vascular volume fractions, Figure 2A shows the computed DR 2 * values for two tissue structures containing only vascular networks (volume fractions of 6% and 9%) and four tissue structures containing only packed ellipsoids (volume fractions ranging from 20% to 60%). At a Dx value of 4p Â 0.2 Â 10 À7 [(CA) ¼ 0.75 mM], corresponding to one-fifth the peak susceptibility difference for a 0.1 mmol/kg dose of Gd-DTPA, the computed DR 2 * values for the 45% and 65% cellular phantoms are 78% higher than that computed for the phantom containing a 9% vascular volume fraction. In general, this difference increases with increasing susceptibility difference between tissue compartments. Figure 2B shows DR 2 * values computed at five different tracer equilibrium concentrations for four different tissue structures with fixed cellular packing volume fraction of 55% and varying vascular volume fractions ranging from 3% to 12%. At a given tracer equilibrium concentration, the computed DR 2 * values are approximately equivalent for all vascular volume fractions. Across vascular volume fractions, a maximum difference of only 4% exists between the computed DR 2 * values, indicating that tissue vascularity has a negligible contribution to the computed DR 2 * values at CA equilibrium, when compared with the effects of CA compartmentalized within the EES.
The dependence of DR 2 * on cellular features (e.g., cell volume fraction and size) is shown in Figure 3A . For a fixed cellular size, as cell volume fraction increases, the DR 2 * first increases and then decreases, reaching a peak value between a cell volume fraction of 30% and 50%, depending on the cell size. In general, as the cell size increases the peak DR 2 * shifts to higher cell volume fractions. The computation in Figure 3A is carried out at a fixed vascular volume fraction of 6% and equilibrium CA concentration corresponding to Dx ¼ 4p Â 0.5 Â 10 À7 . For a given cell volume fraction, increasing the cell size induces larger DR 2 * values. This indicates that, under these simulated conditions the range of tissue structures does not reach the static dephasing regime even for cell sizes near 20 mm. Supporting Figure S1 shows the perturber size dependence of DR 2 * for tissue structures with various cell volume fractions. These results show that the perturber size corresponding to the point where the diffusion independent regime for the gradient echo relaxation rate begins shifts to the right (larger perturber sizes) as cell volume fraction increases. Accordingly, at cellular volume fraction levels (50-60%) observed in vivo (40) , the DR 2 * retains its sensitivity to cell size. For instance a change in cell size from 5 mm to 20 mm results in a 25% increase in DR 2 * for a 25% cell volume fraction but a 45% increase when the cell volume fraction is 50%. Figure 3B shows the dependence of DR 2 * on tissue CA concentration for two tissue structures, both with 6% vascular volume fraction and 50% cellular volume fraction, but different cell sizes. As compared to DR 2 * values computed for the tissue structure with smaller cell size (1 mm), the computed DR 2 * values for the tissue structure built using larger cell size (20 mm) has higher values at each CA concentration levels, owing to its larger field perturbation and a smaller diffusion narrowing process.
The dose response of DR 2 * shown in Figure 3B was used to estimate the TRATE parameter using the slope of a linear regression fit. Figure 3C shows the dependence of TRATE on cell size and volume fraction. For both tissue structures, TRATE increases with increasing cell volume fraction well up to 60%, unlike the DR 2 * values, which peaked near at relatively low cell volume fraction. For a given cell density, TRATE is also shown to increase with cell size.
Experimental TRATE measurements for cell phantoms at various cell volume fractions are shown in Supporting Figure S2 . In general, TRATE increases with increasing cell density for both cell lines. For a given cell density the TRATE values in MEL cells are higher than those found in HL-60 cells.
Example multiecho DSC-MRI derived DR 2 * and DR 1 time curves for C6 glioblastoma, 9L gliosarcoma and normal tissue ROIs are illustrated in Figure 4 . The DR 1 time curves in C6 and 9L tumors and normal tissue are different in both magnitude and shape, illustrating the differences between the CA kinetics within these tissues. The derived DR 2 * time series in 9L tumors exhibited substantial and prolonged (out to 15 min) T 2 * leakage effects. In C6 tumors, these effects, while present, were less pronounced, as the DR 2 * values plateau after 3 min. In normal tissue, the DR 2 * values decrease to nearly precontrast levels immediately after the peak. Figure 5 depicts example C6 and 9L, K trans , v e , ADC, and TRATE maps. Within a given tumor, the TRATE values were spatially heterogeneous. In these examples, the TRATE values were also markedly higher in the 9L tumors as compared to those in the C6 tumors. The TRATE maps exhibited little visual similarity with the other parameters.
Supporting Figure S3 displays representative voxelwise relationships between TRATE and K trans , v e , and ADC corresponding to the median correlation coefficients across all animals. A weak correlation was observed between TRATE and K trans (r ¼ 0.17), v e (r ¼ À0.065), ADC (r ¼ À0.08). Across all the rats, the voxel-wise correlation coefficients, shown in Table 1 , between TRATE and K trans , v e , ADC were low (with a maximum r ¼ 0.54) and diverse. A voxel-wise comparison of the parameters across all the animals revealed no significant association between TRATE and K trans (P ¼ 0.205) or v e (P ¼ 0.442). There was a nonzero statistically significant association with ADC (P ¼ 0.002), which, in part, reflects the large number of observations (voxels) included in the analysis. However, with an R 2 value of only 0.22 there exists a considerable degree of variance in TRATE that is not accounted for in the ADC values. B: A plot of DR 2 * dependence on tracer equilibrium concentration levels, for four tissue structures of fixed cellular structure but different vascular networks. At a given equilibrium concentration level the difference between the computed DR 2 * values is negligible, which indicates that at equilibrium the cellular features rather than the vascular differences drive the DR 2 * values.
Sample histologic images from H&E staining indicate that the C6 tumor cell density (Fig. 6A) is lower than that found in the 9L tumors (Fig. 6B) . Cell nuclei count analysis shows on a group result that 9L tumors contain 30% more cells than C6 tumors (Fig. 7A) ) as shown in Figure 7C . Note that these values of TRATE are substantially larger than the range of T 2 relaxivity values for Gd-DTPA (3.8-4.5 mM À1 s
À1
) measured in water and plasma solutions at 4.7T (35) . Across animals H&E staining estimates of the C6 and 9L tumor cell volume fraction were 56.2 6 4.3% and 74.5 6 3.3%, respectively. Cell sizes were estimated to be 5.02 6 0.6 mm and 8.4 6 1.7 mm for the C6 and 9L tumor cells, respectively. Figure 8 shows the ROI linear regression analysis of TRATE and cell density across all animals. A significant correlation between TRATE and cell density (R 2 ¼ 0.44, P ¼ 0.005) is observed when the tumor cell type is ignored. However, in a mixed linear regression analysis, which accounts for the two cell lines, there was no correlation between TRATE and cell density (P ¼ 0.641), indicating that, within a given cell type, the relationship between TRATE and cell density is unknown. Figure 9 shows example multiecho DSC-MRI data acquired from a ROI in a high-grade glioma patient. Similar to the 9L tumors, the derived DR 2 * time curves exhibit T 2 * leakage effects as shown in Figure 9A . Immediately after the first pass, the DR 2 * only decreases by 40% of the peak value and then slowly decreases over the course of minutes, consistent with kinetics expected for CA extravasation. In contrast, normal tissue DR 2 * values decrease to nearly 85% of the peak value immediately after the peak and quickly plateau near precontrast levels. Example DR 1 time curve computed using T 10 map and the extrapolated dual-echo data for tumor ROI is shown in Figure 9B . Figure 9C shows example maps of the tumor CBF, CBV, v e , ADC, and TRATE. As was the case in the animal tumor models, TRATE is heterogeneous across the tumor. The voxel-wise correlation coefficients, shown in Supporting Table S1 , between TRATE and the other imaging parameters were low (with a maximum r ¼ 0.61) and diverse. On a mean scale, TRATE and ADC exhibited a linear and negative relationship (r 2 ¼ 0.81, P ¼ 0.03, TRATE ¼ 435.86-38.75 Â ADCÂ10 4 ), but on a voxel-wise basis, across the five patients, TRATE showed a statistically significant association with v e (P ¼ 0.003, TRATE ¼ 20.880 þ 4.626 Â v e ). However, similar to the animal data, the voxel-wise correlation coefficients were low, as shown in Supporting Table S1 , and indicate that this association is very small.
DISCUSSION
Previous reports have shown that T 2 * leakage effects influence DSC-MRI data and have suggested a link between their presence and tissue microstructure (14, 15, (27) (28) (29) (41) (42) (43) , but, to date, their biophysical basis is poorly characterized. In this study, we validate, for the first time, using simulations and in vitro and in vivo data, that T 2 * leakage effects, at CA equilibrium, are primarily influenced by cellular characteristics. We also propose a straightforward method to quantify these effects by calculating the TRATE parameter, and show that it can be used to differentiate between brain tumors with histologically distinct cellular properties. A key finding of the computational studies is that at tracer equilibrium the magnetic field perturbations are predominantly influenced by CA compartmentalization around cells. During the first pass of the agent the greatest field perturbation heterogeneity, as expected, is localized around blood vessels. However, at CA equilibrium, the tissue reduces to two effective compartments, the intracellular and extracellular space. Consequently, the cellular features primarily determine the induced field perturbation. Although the field perturbation created by individual cells might be weaker and fall faster than the field perturbation induced by vessels, given the high cell volume fraction of tissues, field perturbations induced by densely packed cells tends to be highly heterogeneous across the voxel, thereby influencing a large number of water protons. Consequently, susceptibility contrast induced parameters, such as TRATE, computed long after the first pass of the CA, are expected to depend on the underlying cellular features.
Simulation results demonstrate that cellular size and volume fraction influence the computed DR 2 * and TRATE values. For all simulated cell volume fractions, the DR 2 * values were larger for tissue structures packed with larger cells compared with those with smaller cells. For a given cell size, the observed dependence of DR 2 * on cell volume fraction (Fig. 3A) can be understood by examining the cell volume fraction induced changes to the computed local magnetic field perturbation (DB) and the standard deviation of the magnetic field perturbation between the simulated grid points within the voxel (DB std ). At low cell volume fractions (e.g., 20%), the addition of cells into the structure will increase both the DB in the vicinity of the new cell and the DB std . At higher cell volume fractions ($35-45%), adding new cells increases DB in their vicinity and the DB std will reach a peak. Beyond this peak, adding more cells will continue to increase the DB, however, as the structure 
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becomes more populated, a higher fraction of the protons will experience similar DB values, causing the DB std to decrease. This observation is consistent with the theoretical treatment of the transverse relaxation rate taken to be proportional to the product of the mean square frequency deviation and the correlation time of the frequency fluctuation (43) (44) (45) . For a fixed diffusion correlation time, the mean square frequency deviation, which is determined by the standard deviation of the field perturbation (DB std ), determines the DR 2 *. Furthermore, the results presented in Figure 3A agrees closely with previously reported DR 2 * dependence on hematocrit measured ex vivo in blood samples (43) . It is interesting to note that over a physiologic range of cell volume fractions that may be expected in viable tissue (e.g., 45-65%) the simulations results in Figure 3A indicate TRATE heterogeneity or contrast most likely reflects variations in cell size. The results shown in Supporting Figure S1 are consistent with previous reports of the characteristic perturber size dependency of relaxation rates. Furthermore, these computational results demonstrate the influence of cell density on the strength of the diffusion narrowing process. At fixed values of B 0 , Dx, and D, the effect of diffusion persists well into large cell sizes as the cell density increases. The presented simulation results are consistent with previous theoretical results based on the Anderson-Weiss mean field theory, where the underlying factors that contribute to transverse relaxation rate variations, including diffusive correlation time and variations in Larmor frequency due to field perturbations, were found to depend on the perturber volume fraction (45) . Consequently, for high cell densities, the perturber size where DR 2 * reaches a plateau occurs at relatively larger cell sizes as compared to lower cell density. This suggests that for physiologically relevant tumor cell volume fractions levels (50-60%) observed in vivo (40), DSC-MRI derived DR 2 * values are highly sensitive to variations in tumor cell size (46) .
The dependence of DR 2 * on C t exhibits a slight deviation from a linear relation (Fig. 3B) . This is consistent with previous studies where a quadratic relation is observed at low CA concentration (13, 47) . However, using CA concentration values that would be expected at equilibrium, 0.1-0.5 mM, a linear regression fit yielded estimates of TRATE with regression values higher than 0.99. Unlike the DR 2 * dependence on cell volume fraction, where the peak DR 2 * occurs at relatively small v i , the computed TRATE values increase with v i beyond 60% and is expected to decrease for high v i values (Fig.  3C ). This shift of the peak to higher v i values results from the quantification of C t as the sum of individual compartment CA concentration weighted by the corresponding volume fractions (C t ¼ v e C e þ v p C p ). For a given equilibrium CA concentration (C eq ) and v p values, the calculated C t values, which are equivalent to (1-v i )C eq , are lower for high cell density structures as compared to those with lower cell density, thereby increasing TRATE. Although a more stringent systematic and realistic simulation study on the relation between TRATE and various physical, physiological, and pulse sequence parameters is warranted, these initial computational results demonstrate that TRATE provides a reasonable range of sensitivity to in vivo cellular volume fraction levels (40). As described above, Sourbron et al recently proposed T 2 *-relaxivity contrast imaging (RCI) as a means to characterize intra-and extravascular CA relaxivities in vivo (16) . In general, TRATE imaging may be considered a subset of RCI as it focuses only on measuring CA relaxivity at tracer equilibrium rather than over the entire time course. Practically, the assessment of TRATE is computationally simpler as it does not rely upon multiple postprocessing steps, including the extraction of parameters from a DCE-MRI two-compartment exchange model and the reliable separation C p and C e time curves. This later step highlights a key difference between RCI and TRATE. Whereas RCI aims to separate the intra-and extravascular CA relaxivities, TRATE, by definition, is the effective tissue CA relaxivity and, thus, only requires measuring the tissue CA concentration, which can be directly computed from the DR 1 time course. In the context of a DSC-MRI brain tumor study, the assessment of TRATE does not involve additional kinetic modeling and may provide a clinically feasible approach for characterizing tumor cellularity.
In vitro cell phantom experiments (Supporting Fig. S2 ) further demonstrated the dependency of TRATE on cell FIG. 9 . Example clinical dual-echo derived DR 2 * and DR 1 time curves and parameter maps. Representative dual-echo DSC-MRI derived DR 2 * and DR 1 in a patient with a recurrent high-grade glioma. A: The tumor ROI DR 2 * time curve exhibits prolonged T 2 * leakage effects, whereas in normal tissue the DR 2 * values, after the first pass, decrease rapidly to precontrast levels. B: Example DR 1 time curve computed using T 10 map and the dual-echo data for tumor ROI is shown. C: Example maps of tumor blood volume, blood flow, v e , ADC, TRATE along with a postcontrast T 1 -weighted anatomical image in a glioma patient. The TRATE map is heterogeneous across the tumor ROI and visually dissimilar to the other parameter maps.
size and density. While the dependence of TRATE on cell density is apparent from Supporting Figure S2 , for a given cell density the difference in TRATE values between the MEL and HL-60 cell lines is likely a result of changes in cellular size and shape.
Both preclinical and clinical multiecho DSC-MRI datasets exhibited substantial T 2 * leakage effects well after the first pass of the CA. Although traditional DSC-MRI exams in brain tumors are typically no more than 3 min, this study confirm the presence of considerable T 2 * effects even out to 10 min following CA injection. With single-echo acquisition methods, the detection of these T 2 * effects is confounded by simultaneous and competing changes in T 1 , which is likely why they are only now being considered as a source of new tissue contrast with MRI. It is also important to note that the TRATE values in the brain tumors studied here were much greater than the microscopic T 2 relaxivity of Gd-DTPA, verifying that mesoscopic susceptibility changes across a voxel are the source of the T 2 * leakage effects.
Histology and ADC measurements indicate that 9L tumors have a higher cell density than that found in C6 tumors. Histological analysis also revealed that the 9L cells were large than C6 cells. Consistent with the computational results showing that TRATE increases with increasing cell volume fraction and cell size, the TRATE values in 9L tumors were significantly higher than those in C6 tumors. A significant correlation between TRATE and cell density was observed when the tumor cell type was ignored (Fig. 8) . However, the lack of correlation between TRATE and cell density within each cell line indicates that other cellular features, in addition to cell density variations (e.g., size, shape, spatial distribution) are driving the differences in TRATE. Moreover this lack of correlation may reflect that the respective cell densities for the C6 and 9L tumor cells are near the peak of the DR 2 * versus cell volume fraction relationship (Fig.  3A) and thereby less sensitive to variations in cell density.
In addition to the dissimilar TRATE values between the C6 and 9L tumor types, there was little to no spatial correlation (Supporting Fig. S3 ), between TRATE and ADC, K trans , or v e , indicating that the variance in the TRATE maps is not accounted for by these parameters and that TRATE is potentially reporting on unique microstructural properties of the tumor tissue. Similar results were found in the human parameter comparisons. The only exception was the ROI mean TRATE versus ADC comparison, which yielded a significant correlation between the parameters. Consistent with the computational and in vitro findings, tumors with low ADC values, potentially reflecting those with high cellularity, also exhibited high TRATE values. Additional studies with more patients is needed to explore this potential relationship, however, because no such correlation was found for the voxel-wise comparison. The dependence of ADC on cellular properties is well established (48) . As shown here, TRATE is sensitive to cell density but also upon other physical or physiological parameters that could alter the susceptibility induced transverse relaxation rates, such as, diffusion, cell membrane permeability, cell size, shape and overall organization (13,29,42,49-52) . While TRATE and ADC depend on similar microstructural features their sensitivities to each will likely differ due to the differences in their underlying contrast mechanisms, which may explain the low voxel-wise correlation coefficients between TRATE and ADC. Further studies are warranted to investigate the specific differences between the sensitivity of TRATE and ADC measurements to tissue cytoarchitecture.
From Figure 4 it is clear that 9L and C6 tumors exhibit marked differences in their DR 1 time courses, which is indicative of differences in vascular hemodynamics, tissue compartment sizes and permeability. Thus, the sensitivity of DR 2 * measurements alone to tumor microstructure, even at CA equilibrium, is likely confounded by heterogeneous and dynamic changes in the tissue CA concentration. Because estimates of TRATE incorporate measures of the tissue CA concentration, the effect of these differences is minimized. TRATE, therefore, is instead influenced by local CA distribution within the EES. This sensitivity is in contrast to other perfusion-based imaging metrics such as PSR, which represents a complex combination of tissue microstructure and hemodynamic effects including blood flow, blood volume, vascular permeability, cell volume fraction, and cellular geometry. Fortunately, the use of multiple-echo DSC-MRI, permits the separation of many of these factors through estimates of DR 1 and DR 2 *, enabling the isolation of tissue geometrical factors (e.g., cell density and distribution). In addition, the acquisition of multiple echoes and calculation of absolute tissue relaxation rates likely makes the method for estimating TRATE less sensitive to pulse sequence parameters when compared with metrics such as PSR (53) . Validation of this point, however, is the subject of future analysis.
Although pulse sequence parameters, such as echo time, may have nominal influence on the estimate of TRATE, the time, after CA injection, during which the measurement is made could be significant. Estimation of TRATE relies on the assumption that the distribution of CA is in a state of equilibrium between the vascular and extravascular extracellular space. With the use of a twocompartment pharmacokinetic modeling (39) it can be shown that, for a range of physiological parameters relevant to brain cancer, CA equilibrium occurs approximately 5 to 7 min after CA injection. For this reason, estimation of TRATE requires a moderately longer DSC-MRI acquisition time. Additionally, physiological phenomena such as tissue necrosis could also influence TRATE measurements. In the case of tumor necrosis, which often occurs in both animal and human brain tumors, diffusion of CA into the necrotic region can occur, resulting in continuously increasing DR 1 (54) . The estimate of TRATE in these regions may be confounded if CA equilibrium is never reached.
As previously indicated, there do exist limitations on the method for calculating TRATE. These limitations, however, are mainly focused on the tissue being analyzed and more specifically its vascular permeability. To reiterate, estimations of TRATE require CA extravasation out of the vasculature. Although computing a threshold for the amount of CA extravasation required is beyond the scope of the work presented here, the change in R 1 after contrast injection should be many times greater than the standard deviation of the baseline R 1 to avoid 782 Semmineh et al.
contributions from noise. Future studies will seek to establish voxel-wise criteria on when TRATE can be reliably measured and its reproducibility. In addition to studies aiming to further characterize the biophysical basis of TRATE, there are numerous opportunities to explore the clinical role of TRATE measurements. Given the previously shown potential of PSR to differentiate between lymphomas, gliomas and brain metastasis based on the presence or absence of T 2 * leakage effects (27) , it is likely that TRATE would show similar differences while at the same time providing a quantitative and pulse sequence independent measure. The sensitivity of TRATE to cytoarchitecture suggests its potential role to assess treatment-induced cytotoxicity, similar to the current use of functional diffusion mapping (55) . Finally, although TRATE was assessed here using a DSC-MRI acquisition, it could just as easily be estimated as part of a multiecho DCE-MRI study or even a multiecho, post-CA injection steady-state exam. The use of these methods would enable the estimation of TRATE, and, therefore, cytoarchitectural features, at higher resolution and in any tissue in or outside the brain using clinically available pulse sequences.
CONCLUSIONS DSC-MRI is commonly used to assess the vascular and hemodynamic status of brain tumors. When acquired with multiecho pulse sequences and precontrast T 1 maps the studies described herein show that, by leveraging T 2 * leakage effects, tumor cellular features can also be interrogated through the parameter TRATE. The sensitivity of TRATE to tissue cytoarchitecture indicate that it could potentially serve as a unique structural signature or "trait" of different types of cancers and may be useful as a biomarker of cancer aggressiveness and early treatment response. Results in preclinical and clinical brain tumors indicate that TRATE provides unique information not present in DCE-MRI kinetic parameters or DWI based ADC maps. Further computational and in vivo studies are needed to systematically characterize the dependency of TRATE on microstructure (e.g., cellular orientation heterogeneity, shape, spatial distribution), establishing its reproducibility and sensitivity to cell density variations in other tumor types and during the course of treatment.
